Halozyme Therapeutics, Inc. $HALO Shares Newly Bought by MRA Advisory Group

MRA Advisory Group acquired a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 6,713 shares of the biopharmaceutical company’s stock, valued at approximately $741,000.

A number of other hedge funds also recently bought and sold shares of the company. MidFirst Bank acquired a new position in shares of Halozyme Therapeutics in the second quarter worth about $27,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Halozyme Therapeutics in the 2nd quarter valued at approximately $28,000. Quantbot Technologies LP acquired a new stake in shares of Halozyme Therapeutics in the second quarter worth $30,000. Caitlin John LLC acquired a new stake in Halozyme Therapeutics during the 2nd quarter worth about $44,000. Finally, Silvant Capital Management LLC purchased a new position in Halozyme Therapeutics during the second quarter valued at approximately $56,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $107.43, for a total value of $2,148,600.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $82,482,605.40. This represents a 2.54% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $102.80, for a total transaction of $167,152.80. Following the completion of the sale, the director owned 40,418 shares of the company’s stock, valued at approximately $4,154,970.40. The trade was a 3.87% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 85,852 shares of company stock valued at $9,158,446. 2.50% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday. Leerink Partners upgraded Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $83.00 to $110.00 in a report on Friday, August 7th. Citizens Jmp boosted their target price on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a research report on Friday, August 7th. TD Cowen lifted their price objective on shares of Halozyme Therapeutics from $96.00 to $105.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Finally, Wall Street Zen raised shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Nine analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $91.20.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO traded up $2.08 during midday trading on Wednesday, reaching $111.80. The stock had a trading volume of 1,155,466 shares, compared to its average volume of 1,926,080. The stock has a market capitalization of $12.69 billion, a P/E ratio of 33.36, a PEG ratio of 0.41 and a beta of 0.88. Halozyme Therapeutics, Inc. has a 1-year low of $61.22 and a 1-year high of $116.85. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31. The firm’s fifty day simple moving average is $104.56 and its 200-day simple moving average is $82.20.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. The firm had revenue of $481.00 million during the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business’s revenue was up 47.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 8.25 EPS for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.